聚醚砜膜片磺化前后对β_2-微球蛋白的吸附能力:膜吸附能力随磺化度增加而发生变化吗?

Sulfonation of polyethersulfone sheets effects on adsorbability of beta 2-microglobulin:Whether the adsorbability changes with increased sulfonation degree?

背景:尿毒症患者在长期透析过程中会出现与透析密切相关的淀粉样变性病症,其主要激发因子是β2-微球蛋白,如何去除血液中β2-微球蛋白一直是研究人员关注的重点。目的:观察不同磺化度、国产与进口来源的两种聚醚砜血液透析膜材在体外静态接触人血清时吸附去除β2-微球蛋白的能力。方法:采用放免法测定膜材在125I-β2-微球蛋白溶液和人血清中,于37℃孵育不同时间后对125I-β2-微球蛋白和β2-微球蛋白的吸附情况。结果与结论:不同来源的聚醚砜膜材对125I-β2-微球蛋白的饱和吸附百分率由大到小依次是高磺化度聚醚砜>低磺化度聚醚砜>未磺化聚醚砜;但在血清孵育体系中,不同材料对β2-微球蛋白的吸附均在30min达到最大吸附值,最后稳定的吸附量由大到小依次是高磺化度聚醚砜>低磺化度聚醚砜>未磺化聚醚砜,不同来源的聚醚砜对β2-微球蛋白的总体趋势完全一致。说明通过用膜吸附方式去除β2-微球蛋白是一种有效的方法。对聚醚砜进行磺化改性可显著提高材料对β2-微球蛋白的吸附去除量,而且随着磺化度增加,膜吸附β2-微球蛋白的量增加。

BACKGROUND：Dialysis-related amyloid may occur during long-term dialysis for patients with uraemia,of which the main evocator is β2-microglobulin（β2M）;therefore,how to eliminate β2M from blood is always the focus of research.OBJECTIVE：To observe ability of removal of β2-microglobulin（β2M）from serum using two kinds of polyethersulfone（PES） membrane materials with various degrees of sulfonation.METHODS：These materials were incubated in radio-labeled β2M（1 25I-β2M）solution and human serum respectively at appointed time at 37℃,and then the amounts of 125I-β2M and serum β2M adsorbed by materials were measured by radio immunoassay.RESULTS AND CONCLUSION：In the125I-β2M system,amounts of 125I-β2M adsorbed by the materials decreased in the following sequence PES with high degree of sulfonationPES with low degree of sulfonationPES,whatever the source of PES was.In the serum system,amounts of β2M adsorbed reached maximums at 30 minutes and the final adsorptions decreased in sequence of PES with high degree of sulfonationPES with low degree of sulfonationPES.Sulfonated PES removed β2M more than PES did and the adsorption of β2M increases with the increase in the degree of sulfonation.Its ability to remove significant amount of β2M may result in less β2M available for incorporation into amyloid.The use of sulfonated PES membranes may lessen the likelihood of development of dialysis-related amyloidosis,which remains a major source of morbidity for patients treated with long-term hemodialysis.